Current State of Melanoma Diagnosis and Treatment

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2019 Aug 2

PMID 31366280

Citations 340

Authors

Lauren E Davis

Sara C Shalin

Alan J Tackett

Affiliations

Soon will be listed here.

Abstract

Melanoma is the deadliest form of skin cancer. In the early stages, melanoma can be treated successfully with surgery alone and survival rates are high, but after metastasis survival rates drop significantly. Therefore, early and correct diagnosis is key for ensuring patients have the best possible prognosis. Melanoma misdiagnosis accounts for more pathology and dermatology malpractice claims than any cancer other than breast cancer, as an early misdiagnosis can significantly reduce a patient's chances of survival. As far as treatment for metastatic melanoma goes, there have been several new drugs developed over the last 10 years that have greatly improved the prognosis of patients with metastatic melanoma, however, a majority of patients do not show a lasting response to these treatments. Thus, new biomarkers and drug targets are needed to improve the accuracy of melanoma diagnosis and treatment. This article will discuss the major advancements of melanoma diagnosis and treatment from antiquity to the present day.

Citing Articles

Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.

Kuras M, Betancourt L, Hong R, Szadai L, Rodriguez J, Horvatovich P Cancers (Basel). 2025; 17(5).

PMID: 40075679 PMC: 11899103. DOI: 10.3390/cancers17050832.

YKL-40 inhibits melanoma progression and metastasis by inducing immune cell infiltration in a mouse model.

Zhang H, Zhao X, Shi M, Han Y, Lu K, Wang H Sci Rep. 2025; 15(1):7426.

PMID: 40033096 PMC: 11876687. DOI: 10.1038/s41598-025-92522-7.

A hybrid fused-KNN based intelligent model to access melanoma disease risk using indoor positioning system.

Mishra S, Das H, Mohapatra S, Khan S, Alojail M, Saraee M Sci Rep. 2025; 15(1):7438.

PMID: 40032864 PMC: 11876441. DOI: 10.1038/s41598-024-74847-x.

Deubiquitination enzyme USP35 negatively regulates MAVS signaling to inhibit anti-tumor immunity.

Zhang H, Zhu J, He R, Xu L, Chen Y, Yu H Cell Death Dis. 2025; 16(1):138.

PMID: 40016186 PMC: 11868397. DOI: 10.1038/s41419-025-07411-8.

Biological potential and therapeutic effectiveness with diverse signaling pathways of phyto-product chicoric acid: a comprehensive review with computational evidence.

Nazir M, Farzeen I, Zafar S, Fatima S, Zafar N, Ashraf A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40014130 DOI: 10.1007/s00210-025-03931-4.

References

Uguen A, Talagas M, Costa S, Duigou S, Bouvier S, De Braekeleer M . A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma. Diagn Pathol. 2015; 10:195. PMC: 4623282. DOI: 10.1186/s13000-015-0431-9. View

Micevic G, Theodosakis N, Bosenberg M . Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics. 2017; 9:34. PMC: 5381063. DOI: 10.1186/s13148-017-0332-8. View

Wolchok J, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L . Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2009; 11(2):155-64. DOI: 10.1016/S1470-2045(09)70334-1. View

Zhang T, Cooper S, Brockdorff N . The interplay of histone modifications - writers that read. EMBO Rep. 2015; 16(11):1467-81. PMC: 4641500. DOI: 10.15252/embr.201540945. View

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

Wang J, Chapman L, Keller M . Challenges to smartphone applications for melanoma detection. Dermatol Online J. 2017; 23(2). View

Luis Manzano J, Layos L, Buges C, de Los Llanos Gil M, Vila L, Martinez-Balibrea E . Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016; 4(12):237. PMC: 4930524. DOI: 10.21037/atm.2016.06.07. View

Li C, Hu Z, Liu Z, Wang L, Strom S, Gershenwald J . Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15(12):2526-32. DOI: 10.1158/1055-9965.EPI-06-0672. View

Koller K, Wang W, Schell T, Cozza E, Kokolus K, Neves R . Malignant melanoma-The cradle of anti-neoplastic immunotherapy. Crit Rev Oncol Hematol. 2016; 106:25-54. DOI: 10.1016/j.critrevonc.2016.04.010. View

10.

Schaefer I, Fletcher C, Hornick J . Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2015; 29(1):4-13. DOI: 10.1038/modpathol.2015.134. View

11.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

12.

Prieto V, Shea C . Use of immunohistochemistry in melanocytic lesions. J Cutan Pathol. 2008; 35 Suppl 2:1-10. DOI: 10.1111/j.1600-0560.2008.01130.x. View

13.

PRADE M, Sancho-Garnier H, Cesarini J, Cochran A . Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer. 1980; 26(2):159-63. DOI: 10.1002/ijc.2910260206. View

14.

Shain A, Bastian B . From melanocytes to melanomas. Nat Rev Cancer. 2016; 16(6):345-58. DOI: 10.1038/nrc.2016.37. View

15.

Weber J . Immunotherapy for melanoma. Curr Opin Oncol. 2010; 23(2):163-9. DOI: 10.1097/CCO.0b013e3283436e79. View

16.

Troxel D . Pitfalls in the diagnosis of malignant melanoma: findings of a risk management panel study. Am J Surg Pathol. 2003; 27(9):1278-83. DOI: 10.1097/00000478-200309000-00012. View

17.

Morton D, Foshag L, Hoon D, Nizze J, Famatiga E, Wanek L . Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992; 216(4):463-82. PMC: 1242654. DOI: 10.1097/00000658-199210000-00010. View

18.

Bergman R, Dromi R, Trau H, Cohen I, Lichtig C . The pattern of HMB-45 antibody staining in compound Spitz nevi. Am J Dermatopathol. 1995; 17(6):542-6. DOI: 10.1097/00000372-199512000-00002. View

19.

Kaufmann S . Paul Ehrlich: founder of chemotherapy. Nat Rev Drug Discov. 2008; 7(5):373. DOI: 10.1038/nrd2582. View

20.

Lee N, Zakka L, Mihm Jr M, Schatton T . Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016; 48(2):177-87. DOI: 10.1016/j.pathol.2015.12.006. View